DEPO MEDROL 40mg/ml price in UAE

Overview

Welcome to Dwaey, specifically on DEPO MEDROL 40mg/ml Injection page.
This medicine contains an important and useful components, as it consists of Methylprednisolone acetate.
DEPO MEDROL 40mg/ml is available in the market in concentration 40mg/ml and in the form of Injection.

PFIZER S.A. is the producer of DEPO MEDROL 40mg/ml and it is imported from BELGIUM, The most popular alternatives of DEPO MEDROL 40mg/ml are listed downward .

Mode Of Action

Methylprednisolone is a synthetic corticosteroid with mainly glucocorticoid activity and minimal mineralocorticoid properties. It decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.

Indication

Anti-inflammatory or immunosuppressive
Allergic conditions

Precaution

Patient w/ heart failure, HTN, DM, GI disease (e.g. diverticulitis, intestinal anastomoses, peptic ulcer, ulcerative colitis), multiple sclerosis, myasthenia gravis, acute MI, cataracts, glaucoma, osteoporosis, history of seizure disorder, thyroid disease. Avoid abrupt withdrawal. Renal and hepatic impairment (including cirrhosis). Childn. Pregnancy and lactation. Monitoring Parameters Monitor BP, blood glucose, electrolytes, growth in childn. Lactation: Drug enters milk; use with caution

Side Effects

Adrenal suppression
anaphylactoid reactions
immunosuppression
acute myopathy
Kaposi's sarcoma
psychiatric disturbances (e.g. depression
euphoria
insomnia
mood swings
personality changes)
increased susceptibility and severity of infections
impaired healing
HTN
Na and fluid retention
CV collapse (high dose)
peptic ulcer
cataract subcapsular
skin atrophy
acne
muscular weakness
growth retardation
decreased blood K; dermal/subdermal skin depression at inj site. Topical: Itching
burning erythema
vesiculation; rarely
folliculitis
hypertrichosis
perioral dermatitis
skin discolouration
allergic skin reactions.

Contra indication

Systemic fungal infections and known hypersensitivity to components.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Loss of corticosteroid-induced adrenal suppression w/ aminoglutethimide. Risk of hypokalaemia w/ K-depleting agents (e.g. amphotericin B, diuretics). Decreased clearance w/ macrolide antibiotics. May decrease serum levels of isoniazid. Increased clearance w/ cholestyramine. Risk of convulsions w/ ciclosporin. Increased risk of arrhythmias w/ digitalis glycosides. Decreased metabolism w/ oestrogens, including OCs. Enhanced metabolism w/ CYP3A4 inducers (e.g. rifampicin, barbiturates). Increased plasma concentrations w/ CYP3A4 inhibitors (e.g. ketoconazole, erythromycin). Risk of GI effects w/ aspirin or other NSAIDs. May increase the anticoagulant effect of warfarin. May reduce the therapeutic effect of antidiabetics. Potentially Fatal: May diminish response to live or live, attenuated vaccines.